What's New for 2021?

As the most comprehensive, industry focused event in the field, we come back in 2021 bigger and better than ever before. With more speakers and more content, take a look at what’s new this year:

Snapshot of New Speakers

  • Kristen Baltgalvis, Director of Biology, Vividion Therapeutics
  • Beth Hoffman, CEO, Origami Therapeutics
  • Gary Choy, CEO, f5 Therapeutics
  • Charu Chaudhary, Principal Scientist, Johnson & Johnson
  • Georg Winter, Principal Investigator, CeMM
  • Harald Weinstabl, Head of Medicinal Chemistry, Boehringer Ingelheim
  • Michael Pourdehnad, Vice President, Bristol-Myers Squibb
  • Sharon Townson, CTO, Monte Rosa Therapeutics
  • Debanu Das, CEO, XPose Therapeutics
  • Ahmed Alkhateeb, Director Oncology External Innovation, Sanofi

New Content


Targeted Protein Degradation 101: If you are new to the TPD field or are looking to get your staff up to speed, look no further than the comprehensive TPD 101 workshop. Establish core skills and understanding in the critical areas of TPD development, covering the fundamental discovery considerations including target selection and optimizing degrader design.

Hear the latest data coming out of the clinic during the dedicated translation and clinical development track on day 1. Covering trials and tribulations and with a dedicated panel discussion reviewing lessons learnt, key challenges, and opportunities beyond oncology.

As the field progresses, more and more degraders are being developed for CNS diseases. This year we have multiple presentations on the development of both monovalent and bifunctional degraders to treat a variety of neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimers.

Discover novel applications of degraders including the development of degraders targeting the DNA damage response, PROTACs to treat SARS-CoV-2 and the use of PHOTACs in neuroscience.

Additional Focus Day

This year we bring you a brand-new post conference focus day on Enhancing Target Engagement for PROTACs & Molecular Glues. Despite advancements in the field PROTACs still suffer from distinct challenges, these include a limited selection for E3 ligases and the requirement for potent target binding; both issues restrict the target scope available for PROTAC.

Rising Stars of TPD

Do you know a Post-Doc that is working on ground-breaking science? In support of the next generation of scientific and business leaders, we are inviting 3 budding pioneers of TPD to join the community and be exposed to the trail blazing developments in this space! Brought to you in exclusive partnership with Kymera Therapeutics, an expert panel of industry leaders will select this year’s winners, providing an opportunity to present a poster and meet with the TPD leaders, take advantage of this opportunity to drive the progress of the next generation of leaders - Submit a Poster Abstract Here